# Oncology

China’s Oncology Frontier: Bioken’s Breakthrough Signals New Global Standard in Lung Cancer Treatment

Chinese biotech firm Bioken has reported record-breaking Phase II clinical results for its bispecific ADC lung cancer treatment, achieving a 100% tumor shrinkage rate in target lesions. Backed by a historic $8.4 billion deal with Bristol Myers Squibb, the company’s success highlights China’s rapid ascent from a generic drug producer to a leader in original pharmaceutical innovation.

NeMo2026年3月31日 16:58

#Bioken#Baili-Tianheng#Antibody-Drug Conjugate

Health

Precision Oncology Gains Ground in China: AmoyDx Secures Regulatory Nod for c-Met Lung Cancer Diagnostic

Amoy Diagnostics has received NMPA approval for its c-Met gene amplification kit, a companion diagnostic for the lung cancer drug Savolitinib. This development marks a vital step in China's push for localized precision oncology and sophisticated personalized medicine tools.

NeTe2026年3月30日 08:29

#AmoyDx#Precision Medicine#Lung Cancer

1 2